SecBot SecBot
SECBOTREPLAY Home › Report › OPK

OPK · OPKO Health announced the initiation of patient dosing in a Phase 1…

OPKO Health, Inc. · PRESS-RELEASE filed Apr 22, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 22, 2026 at 08:00 ET

OPKO Health announced the initiation of patient dosing in a Phase 1 trial for MDX2003, a novel tetraspecific T-cell engager targeting relapsed or refractory B-cell lymphoma. Preclinical data supporting the trial were presented at major medical conferences, marking a key milestone in the development of this first-in-class therapy.

  • OPKO Health subsidiary ModeX Therapeutics has dosed patients in the Phase 1 trial (NCT07249905) of MDX2003, a first-in-class tetraspecific T-cell engager.
  • MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells to enhance tumor killing and prevent immune escape in B-cell lymphoma.
  • Preclinical data demonstrating potent anti-tumor activity were presented at ASH 2025 and ESMO TAT 2026.
  • The study is evaluating safety, tolerability, pharmacokinetics, and immune activity in adult patients with B-cell lymphoma, with dose-escalation and expansion phases.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access